Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma
Primary Purpose
Congenital Glaucoma
Status
Unknown status
Phase
Phase 1
Locations
Azerbaijan
Study Type
Interventional
Intervention
Ologen Collagen Matrix
Combined trabeculotomy-trabeculectomy
Sponsored by
About this trial
This is an interventional treatment trial for Congenital Glaucoma
Eligibility Criteria
Inclusion Criteria:
- Any case diagnosed as congenital glaucoma with enlarged corneal diameter more than 11 mm and intra-ocular pressure above 21 mmHg, including corneal edema or Haab's stria with or without optic disc cupping.
Any case diagnosed as primary or secondary congenital glaucoma to ocular or systemic abnormalities.
Within the age of (0 - 12).
Exclusion Criteria:
- Cases of congenital glaucoma with previous intervention. Age above 12 Yrs. Cases with secondary glaucoma caused by surgical intervention, ocular co-morbidity, medications or trauma
Sites / Locations
- National Centre of Ophthalmology
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Ologen Collagen Matrix Intervention
Combined trabeculotomy-trabeculectomy
Arm Description
Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Outcomes
Primary Outcome Measures
Intraocular pressure(IOP) reduction
"Complete success" is consider for IOP less than 21mmHg(inclusive) with no glaucoma medications and with more than 20% reduction(inclusive) from baseline IOP.
Definition of success rate is calculated in percentage by the number of complete success patients over the total sample size.
"Qualified success" that meets the postoperative IOP requirements with postoperative glaucoma medicaitons and "Failure" of meeting the IOP requirements are the other efficacy parameters.
In the specified time frame, patients will also visit for record at day 7, 30, 90, 180 days, 12, 18, and 24 months.
Secondary Outcome Measures
Postoperative complications and appearances.
Inspections of hyphema, severe anterior chamber reaction, hypotony, supracholoidal hemorrhage, flat anterior chamber, endophthalmitis, choroidal detachment, wound or bleb leak.
Visual acuity (if possible), bleb appearance, and anterior chamber inflammation.
Full Information
NCT ID
NCT02121171
First Posted
April 19, 2014
Last Updated
July 18, 2015
Sponsor
National Centre of Ophthalmology named after academician Zarifa Aliyeva
Collaborators
Aeon Astron Europe B.V.
1. Study Identification
Unique Protocol Identification Number
NCT02121171
Brief Title
Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma
Official Title
Comparative Evaluation of Combined Trabeculotomy-trabeculectomy Versus Combined Trabeculotomy-trabeculectomy With Subconjunctival Implantation of Collagen Matrix Implant for Primary Congenital Glaucoma.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Unknown status
Study Start Date
September 2010 (undefined)
Primary Completion Date
September 2015 (Anticipated)
Study Completion Date
September 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Centre of Ophthalmology named after academician Zarifa Aliyeva
Collaborators
Aeon Astron Europe B.V.
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The objective of this prospective randomised study is to compare the efficacy and safety of ologen CM (Collagen matrix) as adjunct to combined trabeculotomy-trabecuectomy in congenital glaucoma cases, the efficacy being the primary objective and the safety being the secondary. The investigators hypothesize that combined trabeculotomy-trabecuectomy with Ologen collagen matrix implant implantation in congenital glaucoma is a safer procedure and may yield better results than combined trabeculotomy-trabeculectomy approach.
Detailed Description
"Ologen ® CM" is a biodegradable collagen matrix. To prevent episcleral fibrosis and subconjunctival scarring thay may result in the surgical failure in filtration surgery, its sporous matrix modulates the migrations and proliferations of fibroblasts to create a vascular and long-lasting bleb without the adverse effects.
Results of ologen CM studies have been published at conferences and published in peer-reviewed journals; ologen CM is approved in Europe as an aid for tissue repair, and by the FDA in the US as an adjunct in wound management(K080868). In general, over 7,000 ologen CM have been implanted worldwide during the past two years with good results and excellent safety profile.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Congenital Glaucoma
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Ologen Collagen Matrix Intervention
Arm Type
Experimental
Arm Description
Combined trabeculotomy-trabeculectomy with subconjuncitval Ologen matrix implant implantation is a new procedure that has less post operative complications with good results, it is to be applied in children.
Arm Title
Combined trabeculotomy-trabeculectomy
Arm Type
Active Comparator
Arm Description
Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Intervention Type
Device
Intervention Name(s)
Ologen Collagen Matrix
Intervention Description
Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
Intervention Type
Procedure
Intervention Name(s)
Combined trabeculotomy-trabeculectomy
Intervention Description
Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
Primary Outcome Measure Information:
Title
Intraocular pressure(IOP) reduction
Description
"Complete success" is consider for IOP less than 21mmHg(inclusive) with no glaucoma medications and with more than 20% reduction(inclusive) from baseline IOP.
Definition of success rate is calculated in percentage by the number of complete success patients over the total sample size.
"Qualified success" that meets the postoperative IOP requirements with postoperative glaucoma medicaitons and "Failure" of meeting the IOP requirements are the other efficacy parameters.
In the specified time frame, patients will also visit for record at day 7, 30, 90, 180 days, 12, 18, and 24 months.
Time Frame
At postoperative up to 24 months
Secondary Outcome Measure Information:
Title
Postoperative complications and appearances.
Description
Inspections of hyphema, severe anterior chamber reaction, hypotony, supracholoidal hemorrhage, flat anterior chamber, endophthalmitis, choroidal detachment, wound or bleb leak.
Visual acuity (if possible), bleb appearance, and anterior chamber inflammation.
Time Frame
At postoperative up to 24 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Any case diagnosed as congenital glaucoma with enlarged corneal diameter more than 11 mm and intra-ocular pressure above 21 mmHg, including corneal edema or Haab's stria with or without optic disc cupping.
Any case diagnosed as primary or secondary congenital glaucoma to ocular or systemic abnormalities.
Within the age of (0 - 12).
Exclusion Criteria:
Cases of congenital glaucoma with previous intervention. Age above 12 Yrs. Cases with secondary glaucoma caused by surgical intervention, ocular co-morbidity, medications or trauma
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nigar Makhmudova
Organizational Affiliation
Ophthalmologist at National Centre of Ophthalmology
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Centre of Ophthalmology
City
Baku
Country
Azerbaijan
12. IPD Sharing Statement
Learn more about this trial
Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma
We'll reach out to this number within 24 hrs